Amgen Inc
AMGN290.920USD
+2.360+0.82%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
156.19BMarket Cap
38.19P/E TTM
More Details of Amgen Inc Company
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
Company codeAMGN
Company nameAmgen Inc
IPO dateJun 17, 1983
Founded at1986
CEOMr. Robert A. (Bob) Bradway
Number of employees28000
Security typeOrdinary Share
Fiscal year-endJun 17
AddressOne Amgen Center Drive
CityTHOUSAND OAKS
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code91320-1799
Phone18054471000
Websitehttps://www.amgen.com/
Company codeAMGN
IPO dateJun 17, 1983
Founded at1986
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
560.43K
+23.31%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
67.76K
+5.28%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
40.10K
+15.22%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
16.38K
+2.37%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.39K
+12.92%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
8.96K
+11.36%
Ms. Nancy A. Grygiel
Ms. Nancy A. Grygiel
Senior Vice President, Chief Compliance Officer
Senior Vice President, Chief Compliance Officer
7.05K
+16.11%
Dr. Brian J. Druker, M.D.
Dr. Brian J. Druker, M.D.
Independent Director
Independent Director
6.76K
+2.49%
Dr. Wanda M. Austin, Ph.D.
Dr. Wanda M. Austin, Ph.D.
Independent Director
Independent Director
6.54K
--
Ms. Amy E. Miles
Ms. Amy E. Miles
Independent Director
Independent Director
4.03K
+2.70%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert A. (Bob) Bradway
Mr. Robert A. (Bob) Bradway
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
560.43K
+23.31%
Mr. Esteban Santos
Mr. Esteban Santos
Executive Vice President - Operations
Executive Vice President - Operations
67.76K
+5.28%
Mr. Murdo Gordon
Mr. Murdo Gordon
Executive Vice President - Global Commercial Operations
Executive Vice President - Global Commercial Operations
40.10K
+15.22%
Dr. Tyler Jacks
Dr. Tyler Jacks
Independent Director
Independent Director
16.38K
+2.37%
Mr. Derek Miller
Mr. Derek Miller
Senior Vice President - Human Resources
Senior Vice President - Human Resources
9.39K
+12.92%
Ms. Rachna Khosla
Ms. Rachna Khosla
Senior Vice President - Business Development
Senior Vice President - Business Development
8.96K
+11.36%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Other products
5.63B
16.84%
Prolia
4.37B
13.09%
Enbrel
3.32B
9.92%
XGEVA
2.23B
6.66%
Repatha
2.22B
6.65%
Other
15.66B
46.84%
By RegionUSD
Name
Revenue
Proportion
US
23.30B
69.71%
ROW
8.72B
26.10%
Other revenues
1.40B
4.18%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Other products
5.63B
16.84%
Prolia
4.37B
13.09%
Enbrel
3.32B
9.92%
XGEVA
2.23B
6.66%
Repatha
2.22B
6.65%
Other
15.66B
46.84%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.76%
State Street Global Advisors (US)
5.47%
BlackRock Institutional Trust Company, N.A.
5.36%
Charles Schwab Investment Management, Inc.
2.46%
PRIMECAP Management Company
2.42%
Other
74.53%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.76%
State Street Global Advisors (US)
5.47%
BlackRock Institutional Trust Company, N.A.
5.36%
Charles Schwab Investment Management, Inc.
2.46%
PRIMECAP Management Company
2.42%
Other
74.53%
Type
Shareholder
Proportion
Investment Advisor
40.14%
Investment Advisor/Hedge Fund
29.75%
Research Firm
4.22%
Pension Fund
2.32%
Bank and Trust
2.07%
Hedge Fund
1.61%
Sovereign Wealth Fund
1.21%
Insurance Company
0.57%
Individual Investor
0.16%
Other
17.93%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
4424
443.65M
82.51%
+4.81M
2024Q4
4466
443.40M
82.54%
+89.78K
2024Q3
4316
438.01M
81.42%
-5.13M
2024Q2
4284
437.79M
81.61%
-4.94M
2024Q1
4192
436.25M
81.40%
-5.11M
2023Q4
4150
435.28M
81.36%
+42.25K
2023Q3
3990
429.94M
80.36%
-4.48M
2023Q2
3936
426.14M
79.65%
-4.34M
2023Q1
3951
427.29M
80.00%
-4.36M
2022Q4
3946
428.59M
80.25%
-5.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
52.49M
9.77%
+346.49K
+0.66%
Dec 31, 2024
State Street Global Advisors (US)
29.43M
5.48%
+117.40K
+0.40%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
28.79M
5.36%
+444.90K
+1.57%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
13.21M
2.46%
+2.67M
+25.38%
Dec 31, 2024
PRIMECAP Management Company
13.00M
2.42%
-1.25M
-8.80%
Dec 31, 2024
Geode Capital Management, L.L.C.
12.48M
2.32%
+352.14K
+2.90%
Dec 31, 2024
Capital International Investors
12.21M
2.27%
+3.50M
+40.10%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
11.12M
2.07%
+149.28K
+1.36%
Feb 28, 2025
Morgan Stanley Smith Barney LLC
8.37M
1.56%
-185.43K
-2.17%
Dec 31, 2024
Wells Fargo Advisors
6.91M
1.29%
-231.48K
-3.24%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
VanEck Biotech ETF
15.63%
FT Vest DJIA Dogs 10 Target Income ETF
13.78%
Invesco Nasdaq Biotechnology ETF
9.01%
ProShares Ultra Nasdaq Biotechnology
8.09%
iShares Biotechnology ETF
7.23%
Amplify Weight Loss Drug & Treatment ETF
5.87%
Amplify CWP Enhanced Dividend Income ETF
5.51%
Invesco Biotechnology & Genome ETF
5.22%
Invesco Pharmaceuticals ETF
5.18%
Monarch Blue Chips Core ETF
4.58%
View more
VanEck Biotech ETF
Proportion15.63%
FT Vest DJIA Dogs 10 Target Income ETF
Proportion13.78%
Invesco Nasdaq Biotechnology ETF
Proportion9.01%
ProShares Ultra Nasdaq Biotechnology
Proportion8.09%
iShares Biotechnology ETF
Proportion7.23%
Amplify Weight Loss Drug & Treatment ETF
Proportion5.87%
Amplify CWP Enhanced Dividend Income ETF
Proportion5.51%
Invesco Biotechnology & Genome ETF
Proportion5.22%
Invesco Pharmaceuticals ETF
Proportion5.18%
Monarch Blue Chips Core ETF
Proportion4.58%
Dividend
A total of
21.35B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 10, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 07, 2025
Feb 14, 2025
Oct 25, 2024
AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024
Nov 18, 2024
Dec 09, 2024
Nov 18, 2024
Aug 02, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 06, 2024
Aug 16, 2024
Mar 06, 2024
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024
May 17, 2024
Jun 07, 2024
May 16, 2024
Dec 12, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024
Feb 16, 2024
Mar 07, 2024
Feb 15, 2024
Oct 24, 2023
AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023
Nov 17, 2023
Dec 08, 2023
Nov 16, 2023
Aug 01, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 08, 2023
Aug 17, 2023
Mar 07, 2023
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023
May 18, 2023
Jun 08, 2023
May 17, 2023
Dec 12, 2022
AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 08, 2023
Feb 14, 2023
Oct 28, 2022
AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022
Nov 17, 2022
Dec 08, 2022
Nov 16, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data